Gentium is a leader in Europe for Urokinase production. The drug is used in the management of thromboembolic disorders such as, deep venous thrombosis, pulmonary embolism, acute myocardial infarction and peripheral arterial thromboembolism. Urokinase is an enzyme isolated from human urine that activates plasminogen. It is a thrombolytic drug which directly converts plasminogen to fibrinolysin, a proteolytic enzyme with fibrinolytic effects. It is also important in maintaining catheter patency. Processes have been instituted to remove adventitious agents occurring in the starting material. For urokinase, we have added a second viral clearance step that exceeds other product approaches.
Gentium supplies urokinase to international pharmaceutical companies who market the drug product in their own countries.